Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 5/20 | 0.58 |
| ▸ | HTR1D | P28221 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 9/20 | 0.43 |
| ▸ | NOS1 | P29475 | 9/20 | 0.43 |
| ▸ | NOS2 | P35228 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252917 | 1.00 | HTR7 (0.59) | HTR7HTR6HTR1DNOS3NOS1 | |
| SCHEMBL7699226 | 0.97 | HTR7 (0.58) | HTR7HTR6HTR1DNOS3NOS1 | |
| SCHEMBL7252947 | 0.84 | HTR7 (0.53) | HTR7HTR6HTR1DNOS3NOS1 | |
| SCHEMBL7253245 | 0.81 | HTR6 (0.60) | HTR7HTR6HTR1DNOS3NOS1 | |
| SCHEMBL7253243 | 0.81 | HTR6 (0.60) | HTR7HTR6HTR1DNOS3NOS1 | |
| SCHEMBL7252886 | 0.81 | HTR7 (0.42) | HTR7HTR6HTR1DDRD2DRD3 | |
| SCHEMBL7253030 | 0.78 | HTR6 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253026 | 0.78 | HTR6 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253409 | 0.78 | HTR6 (0.59) | HTR6HTR1DCHRNB1CHRNB2CHRNB4 | |
| SCHEMBL7253410 | 0.77 | HTR6 (0.67) | HTR7HTR6NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | claimed |
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR7 73/4885HTR6 368/4885HTR1D 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.